Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. trial

G. Mustacchi, S. Milani, A. Pluchinotta, A. De Matteis, A. Rubagotti, A. Perrota

Research output: Contribution to journalArticle

Abstract

A multicentre trial in operable breast cancer in patients aged over 70 years compared tamoxifen alone (starting with a loading dose of 160 mg on the first day) with surgery plus adjuvant tamoxifen. 473 patients were recruited with a median follow up of 36 months. Local progression occurred in 15/237 patients in the surgical arm versus 60/236 in the tamoxifen alone arm (p=0.000). There were 48 deaths in the surgical arm and 41 in the other one (p= 0.67). Distant metastases occurred in 33/237 patients in the surgical arm versus 19/236 in the tamoxifen alone arm (p= 0.058). In elderly patients with operable breast cancer surgery is indicated. Tamoxifen alone is an adequate alternative in frail patients. A loading dose of Tamoxifen may be useful in preventing the expression of the metastatizing phenotype. In any case, delayed surgery does not prejudice the overall survival.

Original languageEnglish
Pages (from-to)2197-2200
Number of pages4
JournalAnticancer Research
Volume14
Issue number5 B
Publication statusPublished - 1994

Keywords

  • Breast cancer
  • Elderly patients
  • Surgery
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. trial'. Together they form a unique fingerprint.

  • Cite this

    Mustacchi, G., Milani, S., Pluchinotta, A., De Matteis, A., Rubagotti, A., & Perrota, A. (1994). Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. trial. Anticancer Research, 14(5 B), 2197-2200.